BT and Accelrys Technologies Unlock Value in Big Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BT and Accelrys Technologies Unlock Value in Big Data


British Telecommunications (BT) and Accelrys are collaborating to provide solutions for analyzing massive datasets using BT for Life Sciences Cloud Compute Platform combined with Accelrys Enterprise Platform and Accelrys Pipeline Pilot software, the companies announced in a press release.  The tools can be used to mine information on healthcare topics from very large datasets.

BT has collated publically available health system and social care information into a research repository intended for use by the life sciences and healthcare industries as well as academia, initially hosted in the United States and United Kingdom, but available for global access. Such data can provide valuable insight into a number of healthcare topics, such as disease prevalence, impact of ethnic mix and adverse drug reactions. However, the information is often contained in very large datasets and may be unstructured in nature. The datasets can be analyzed using the BT and Accelrys tools.

“The generation of ever-increasing amounts of health data is both a blessing and a curse, as they are data-rich, but often information-poor,” said Leif Pedersen, senior vice president of marketing, product management and corporate development at Accelrys, in the press release. “Working with BT, we’ve shown that we can deliver meaningful and valuable insights from these huge datasets.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
10%
Protecting the supply chain
40%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here